Another study has reported that concurrent blockade of the PI3K/AKT/mTOR (with mTOR inhibitor AZD8055) and RAS/MEK/ERK (with MEK inhibitor AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth [39]. The gene discussed is AKT1; the disease is rhabdomyosarcoma.